Zobrazeno 1 - 10
of 17
pro vyhledávání: '"M. E. van Linde"'
Autor:
T. Numan, S. D. Kulik, B. Moraal, J. C. Reijneveld, C. J. Stam, P. C. de Witt Hamer, J. Derks, A. M. E. Bruynzeel, M. E. van Linde, P. Wesseling, M. C. M. Kouwenhoven, M. Klein, T. Würdinger, F. Barkhof, J. J. G. Geurts, A. Hillebrand, L. Douw
Publikováno v:
Scientific Reports, Vol 11, Iss 1, Pp 1-10 (2021)
Abstract Non-invasively measured brain activity is related to progression-free survival in glioma patients, suggesting its potential as a marker of glioma progression. We therefore assessed the relationship between brain activity and increasing tumor
Externí odkaz:
https://doaj.org/article/db7a744192a044f1a2cdce3407df8c2d
Autor:
M Schuur, Mathilde C.M. Kouwenhoven, L de Glopper, F E L van den Elzen, M. E. van Linde, M Sintemaartensdijk, A N van der Vegt, N Grun, Tjeerd J. Postma, J Osinga
Publikováno v:
Neuro Oncol
BACKGROUND Glioblastoma has an infiltrative growth pattern that makes complete resection of the tumor virtually impossible. Sooner or later the tumor progresses, even after aggressive treatment with maximal safe resection, radiotherapy and/or chemoth
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f26585b03551878dc0e5caee325af119
https://europepmc.org/articles/PMC8427454/
https://europepmc.org/articles/PMC8427454/
Autor:
J Osinga, Tjeerd J. Postma, P. de Haan, A N van der Vegt, M Schuur, William P. Vandertop, Mathilde C.M. Kouwenhoven, M. E. van Linde, N Grun, R.E. de Vries
Publikováno v:
Neuro-Oncology, 23, 47-47. Oxford University Press
Van der Vegt, A N, de Vries, R, Osinga, J, Grun, N, Postma, T J, de Haan, P F, van Linde, M E, Vandertop, W P, Schuur, M & Kouwenhoven, M C M 2021, ' P14.51 Can patients with a suspected high-grade glioma receive tumor treatment during pregnancy safely? ', Neuro-Oncology, vol. 23, pp. 47-47 .
Van der Vegt, A N, de Vries, R, Osinga, J, Grun, N, Postma, T J, de Haan, P F, van Linde, M E, Vandertop, W P, Schuur, M & Kouwenhoven, M C M 2021, ' P14.51 Can patients with a suspected high-grade glioma receive tumor treatment during pregnancy safely? ', Neuro-Oncology, vol. 23, pp. 47-47 .
BACKGROUND Diagnosis of a glioma during pregnancy has ethical and medical dilemmas; treatment of the mother may harm the unborn child, but a too conservative approach towards tumor treatment can compromise the survival of the mother. In patients with
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e1bf3a26d5ec6614a68470f20582492d
https://research.vumc.nl/en/publications/c9374680-8384-407c-b8a0-d7f16a896a31
https://research.vumc.nl/en/publications/c9374680-8384-407c-b8a0-d7f16a896a31
Autor:
Mathilde C.M. Kouwenhoven, B. Moraal, Anna M.E. Bruynzeel, P. C. de Witt Hamer, Jaap C. Reijneveld, Frederik Barkhof, Martin Klein, Tianne Numan, S. D. Kulik, Pieter Wesseling, Cornelis J. Stam, Jeroen J. G. Geurts, Arjan Hillebrand, Linda Douw, M. E. van Linde, Thomas Wurdinger, Jolanda Derks
Publikováno v:
Numan, T, Kulik, S D, Moraal, B, Reijneveld, J C, Stam, C J, de Witt Hamer, P C, Derks, J, Bruynzeel, A M E, van Linde, M E, Wesseling, P, Kouwenhoven, M C M, Klein, M, Würdinger, T, Barkhof, F, Geurts, J J G, Hillebrand, A & Douw, L 2021, ' Non-invasively measured brain activity and radiological progression in diffuse glioma ', Scientific Reports, vol. 11, no. 1, 18990, pp. 18990 . https://doi.org/10.1038/s41598-021-97818-y, https://doi.org/10.1038/s41598-021-97818-y
Scientific Reports
Scientific Reports, Vol 11, Iss 1, Pp 1-10 (2021)
Scientific Reports, 11(1):18990. Nature Publishing Group
Scientific Reports
Scientific Reports, Vol 11, Iss 1, Pp 1-10 (2021)
Scientific Reports, 11(1):18990. Nature Publishing Group
Non-invasively measured brain activity is related to progression-free survival in glioma patients, suggesting its potential as a marker of glioma progression. We therefore assessed the relationship between brain activity and increasing tumor volumes
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::814f97b338f2bbffcb9e373f51bafd9c
https://doi.org/10.1101/2021.01.31.21250524
https://doi.org/10.1101/2021.01.31.21250524
Autor:
P. C. de Witt Hamer, M. E. van Linde, M. Weber, Johannes C.F. Ket, J. G. Rottgering, M. H. N. Chagas, Martin Klein, Mathilde C.M. Kouwenhoven, P. M. van de Ven, K. Bacher Svendsen, Linda Douw, V. Belgers, J. Lopez-Sendon, M.G.M. Olde Rikkert
Publikováno v:
Belgers, V, Röttgering, JG, Douw, L, Klein, M, van de Ven, PM, Ket, J C F, Svendsen, K B, Weber, M, Lopez-Sendon, J L, Rikkert, M O, Chagas, M H N, van Linde, ME, Kouwenhoven, MCM & Versélewel de Witt Hamer, PC 2021, ' P12.07 The potential of cannabinoids to improve quality of life in glioma patients: A meta-analysis in patients with neurological and oncological disease ', Neuro-Oncology . https://doi.org/10.1093/neuonc/noab180.109
Neuro-Oncology. Oxford University Press
Neuro-Oncology. Oxford University Press
BACKGROUND Gliomas are primary brain tumors with a dismal prognosis. Reducing symptoms and maintaining quality of life (QoL) are main treatment aims in glioma patients. Mental well-being is an important subdomain of QoL. Cannabinoids have been sugges
Autor:
J. G. Rottgering, P. C. de Witt Hamer, Martin Klein, M Schuur, Linda Douw, Mathilde C.M. Kouwenhoven, M. E. van Linde, V. Belgers, C. M. Nijboer, Tjeerd J. Postma
Publikováno v:
Neuro-Oncology. Oxford University Press
Röttgering, JG, Belgers, V, Kouwenhoven, MCM, Schuur, M, Postma, TJ, Nijboer, C M, van Linde, ME, Versélewel de Witt Hamer, PC, Douw, L & Klein, M 2021, ' P12.02 Symptoms of patients with diffuse glioma during stable disease as a potential target for treatment ', Neuro-Oncology . https://doi.org/10.1093/neuonc/noab180.104
Röttgering, JG, Belgers, V, Kouwenhoven, MCM, Schuur, M, Postma, TJ, Nijboer, C M, van Linde, ME, Versélewel de Witt Hamer, PC, Douw, L & Klein, M 2021, ' P12.02 Symptoms of patients with diffuse glioma during stable disease as a potential target for treatment ', Neuro-Oncology . https://doi.org/10.1093/neuonc/noab180.104
BACKGROUND Patients with diffuse glioma experience many tumor- and treatment-related symptoms, including fatigue, cognitive deficits, and anxiety. It remains unclear how the frequency and burden of these symptoms change over time and specifically whi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::43a50c44fa32fb1207ae7b488de4c889
https://research.vumc.nl/en/publications/fa74b0ab-3f99-4075-8327-01eea9d779fa
https://research.vumc.nl/en/publications/fa74b0ab-3f99-4075-8327-01eea9d779fa
Autor:
M Schuur, Joost J.C. Verhoeff, J.F. de Haan, Mathilde C.M. Kouwenhoven, Tjeerd J. Postma, C A den Otter, P. C. de Witt Hamer, N Grun, Birgit I. Lissenberg-Witte, M Sintemaartensdijk, F.Y.F.L. De Vos, F E L van den Elzen, Anna M.E. Bruynzeel, J Osinga, A N van der Vegt, Joost L M Jongen, M. E. van Linde
Publikováno v:
Neuro Oncol
BACKGROUND Besides early tumour progression, standard first-line radiation with concurrent and adjuvant temozolomide in de novo glioblastoma patients is abrogated frequently by severe haematological toxicity. This leads to treatment delays with unkno
Autor:
U. K. Abdul, Cyrillo G. Brahm, Rudolf S N Fehrmann, Bart A. Westerman, Henk M. W. Verheul, M. E. van Linde, Annemiek M E Walenkamp
BACKGROUND: Glioblastoma (GBM), the most common primary brain tumor in adults, universally recurs with dismal prognosis. Therefore, there is a need for new and more effective treatment strategies. Here, we aim to discover new therapeutic targets in G
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9027b4cc53b6b0f28042d357b9b93b18
https://europepmc.org/articles/PMC6144369/
https://europepmc.org/articles/PMC6144369/
Autor:
Lale Erdem-Eraslan, Roger Stupp, Pim J. French, Th Gorlia, Gail Ryan, Olivier Chinot, F. Dhermain, J.M.M. Gijtenbeek, Monika E. Hegi, P. A. E. Sillevis Smitt, Johan M. Kros, Maaike J. Vos, Carmen Balana, M. Ben Hassel, M. E. van Linde, Gao Y, Khê Hoang-Xuan, A. von Deimling, Brigitta G. Baumert, A. A. Brandes, Bas Weenink, Roelien H. Enting, Warren P. Mason, M. J. van den Bent
Publikováno v:
Gao, Y, Weenink, B, van den Bent, M J, Erdem-Eraslan, L, Kros, J M, Sillevis Smitt, P A E, Hoang-Xuan, K, Brandes, A A, Vos, M, Dhermain, F, Enting, R, Ryan, G F, Chinot, O, Ben Hassel, M, van Linde, M E, Mason, W P, Gijtenbeek, J M M, Balana, C, von Deimling, A, Gorlia, T, Stupp, R, Hegi, M E, Baumert, B G & French, P J 2018, ' Expression-based intrinsic glioma subtypes are prognostic in low-grade gliomas of the EORTC22033-26033 clinical trial ', European Journal of Cancer, vol. 94, pp. 168-178 . https://doi.org/10.1016/j.ejca.2018.02.023
European Journal of Cancer
European Journal of Cancer, 2018, 94, pp.168-178. ⟨10.1016/j.ejca.2018.02.023⟩
European Journal of Cancer, 94, 168-178. Elsevier Ltd.
European Journal of Cancer, Elsevier, 2018, 94, pp.168-178. 〈10.1016/j.ejca.2018.02.023〉
European Journal of Cancer, 94, pp. 168-178
European Journal of Cancer, Elsevier, 2018, 94, pp.168-178. ⟨10.1016/j.ejca.2018.02.023⟩
European Journal of Cancer, 94, 168-178
European Journal of Cancer, 94, 168-178. Pergamon
European Journal of Cancer, 94, 168-178. ELSEVIER SCI LTD
European journal of cancer (Oxford, England, 94, 168-178. Elsevier Limited
r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol
instname
European Journal of Cancer
European Journal of Cancer, 2018, 94, pp.168-178. ⟨10.1016/j.ejca.2018.02.023⟩
European Journal of Cancer, 94, 168-178. Elsevier Ltd.
European Journal of Cancer, Elsevier, 2018, 94, pp.168-178. 〈10.1016/j.ejca.2018.02.023〉
European Journal of Cancer, 94, pp. 168-178
European Journal of Cancer, Elsevier, 2018, 94, pp.168-178. ⟨10.1016/j.ejca.2018.02.023⟩
European Journal of Cancer, 94, 168-178
European Journal of Cancer, 94, 168-178. Pergamon
European Journal of Cancer, 94, 168-178. ELSEVIER SCI LTD
European journal of cancer (Oxford, England, 94, 168-178. Elsevier Limited
r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol
instname
Introduction: The European Organisation for Research and Treatment of Cancer (EORTC) 22033-26033 clinical trial (NCT00182819) investigated whether initial temozolomide (TMZ) chemotherapy confers survival advantage compared with radiotherapy (RT) in l
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4162fea92c3a37e28fc354eb2873bec4
https://research.vumc.nl/en/publications/58893c65-c797-4e1d-be63-f6fd69c6ec74
https://research.vumc.nl/en/publications/58893c65-c797-4e1d-be63-f6fd69c6ec74
Autor:
Jan Kraan, Jan-Willem Gratama, HM Oosterkamp, F.Y.F.L. De Vos, Annemiek M E Walenkamp, B. van der Holt, Laurens V. Beerepoot, Walter Taal, A. Otten, M. E. van Linde, Nick Beije, M. J. van den Bent, Stefan Sleijfer, Monique Hanse, René M. Vernhout
Publikováno v:
British Jounal of Cancer, 113(2), 226-231. Nature Publishing Group
British Journal of Cancer, 113(2), 226-231. Nature Publishing Group
British Journal of Cancer
British Journal of Cancer, 113(2), 226. Nature Publishing Group
Beije, N, Kraan, J, Taal, W, van der Holt, B, Oosterkamp, H M, Walenkamp, A M, Beerepoot, L, Hanse, M, van Linde, M E, Otten, A, Vernhout, R M, de Vos, F Y F, Gratama, J W, Sleijfer, S & van den Bent, M J 2015, ' Prognostic value and kinetics of circulating endothelial cells in patients with recurrent glioblastoma randomised to bevacizumab plus lomustine, bevacizumab single agent or lomustine single agent. A report from the Dutch Neuro-Oncology Group BELOB trial ', British Journal of Cancer, vol. 113, no. 2, pp. 226-231 . https://doi.org/10.1038/bjc.2015.191
British Journal of Cancer, 113(2), 226-231. Nature Publishing Group
British Journal of Cancer
British Journal of Cancer, 113(2), 226. Nature Publishing Group
Beije, N, Kraan, J, Taal, W, van der Holt, B, Oosterkamp, H M, Walenkamp, A M, Beerepoot, L, Hanse, M, van Linde, M E, Otten, A, Vernhout, R M, de Vos, F Y F, Gratama, J W, Sleijfer, S & van den Bent, M J 2015, ' Prognostic value and kinetics of circulating endothelial cells in patients with recurrent glioblastoma randomised to bevacizumab plus lomustine, bevacizumab single agent or lomustine single agent. A report from the Dutch Neuro-Oncology Group BELOB trial ', British Journal of Cancer, vol. 113, no. 2, pp. 226-231 . https://doi.org/10.1038/bjc.2015.191
Background: Angiogenesis is crucial for glioblastoma growth, and anti-vascular endothelial growth factor agents are widely used in recurrent glioblastoma patients. The number of circulating endothelial cells (CECs) is a surrogate marker for endotheli